Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma
Shigeo GodoYoshitaro YoshidaNaoki KawamoritaKoji MitsuzukaYu KawazoeMotoo FujitaDaisuke KudoRyosuke NomuraHiroaki ShimokawaShigeki Kushimoto
著者情報
ジャーナル オープンアクセス

2018 年 57 巻 19 号 p. 2895-2900

詳細
抄録

Axitinib has emerged as a promising antineoplastic agent for the treatment of advanced renal cell carcinoma. Although the administration of axitinib was well-tolerated in clinical trials, the real-world safety and tolerability remain unverified. We herein report a patient with metastatic renal cell carcinoma who suddenly developed life-threatening hyperkalemia following the initiation of axitinib treatment. Although hyperkalemia has been reported with an incidence of <10%, acute severe hyperkalemia may be a considerably critical adverse event of axitinib therapy, especially in patients with risk factors for hyperkalemia. An abundance of caution for unusual and unpredictable toxicities is warranted when using axitinib.

著者関連情報
© 2018 by The Japanese Society of Internal Medicine
前の記事 次の記事
feedback
Top